Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series.
Oliver JL, Sadorge C, Boisnard F, Snape MD, Tomlinson R, Mann R, Rudd P, Bhakthavalsala S, Faust SN, Heath PT, Hughes SM, Borrow R, Thomas S, Finn A. Oliver JL, et al. Among authors: boisnard f. Vaccine. 2020 Jul 31;38(35):5718-5725. doi: 10.1016/j.vaccine.2020.06.015. Epub 2020 Jul 10. Vaccine. 2020. PMID: 32654902 Clinical Trial.
Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B; Pentavac study group. Langue J, et al. Among authors: boisnard f. Vaccine. 2004 Mar 29;22(11-12):1406-14. doi: 10.1016/j.vaccine.2003.10.026. Vaccine. 2004. PMID: 15063563 Clinical Trial.
Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster.
Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B; Pentavac Study Group. Mallet E, et al. Among authors: boisnard f. Vaccine. 2004 Mar 29;22(11-12):1415-22. doi: 10.1016/j.vaccine.2003.10.025. Vaccine. 2004. PMID: 15063564 Clinical Trial.
Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine.
Kitchin N, Southern J, Morris R, Borrow R, Fiquet A, Boisnard F, Thomas S, Miller E. Kitchin N, et al. Among authors: boisnard f. Vaccine. 2009 Aug 13;27(37):5096-102. doi: 10.1016/j.vaccine.2009.06.049. Epub 2009 Jun 30. Vaccine. 2009. PMID: 19573637 Clinical Trial.
Immunogenicity and safety of fully liquid DTaP₅-IPV-Hib compared with DTaP₃-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study.
Grimprel E, Wysocki J, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Grimprel E, et al. Among authors: boisnard f. Vaccine. 2011 Oct 6;29(43):7370-8. doi: 10.1016/j.vaccine.2011.07.078. Epub 2011 Jul 30. Vaccine. 2011. PMID: 21807056 Clinical Trial.
Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: a phase III, modified double-blind, randomized, controlled, multicenter study.
Berner R, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Berner R, et al. Among authors: boisnard f. Vaccine. 2012 Jul 27;30(35):5270-7. doi: 10.1016/j.vaccine.2012.05.064. Epub 2012 Jun 9. Vaccine. 2012. PMID: 22691430 Clinical Trial.
Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV/Hib vaccine administered at 3, 5, and 12 months of age.
Vesikari T, Silfverdal SA, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Vesikari T, et al. Among authors: boisnard f. Clin Vaccine Immunol. 2013 Oct;20(10):1647-53. doi: 10.1128/CVI.00414-13. Epub 2013 Aug 21. Clin Vaccine Immunol. 2013. PMID: 23966556 Free PMC article. Clinical Trial.
A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. Vesikari T, et al. Among authors: boisnard f. Pediatr Infect Dis J. 2017 Feb;36(2):209-215. doi: 10.1097/INF.0000000000001406. Pediatr Infect Dis J. 2017. PMID: 27846055 Clinical Trial.
19 results